APA (7th ed.) Citation

Willis, E., Verrelle, J., Banerjee, E., Assenmacher, C., Tarrant, J. C., Skuli, N., . . . Radaelli, E. (2023). 22 Humanized NOG-EXL mice exhibit improved overall survival and less severe myeloid cell activation relative to humanized NSG-SGM3 mice. Journal for immunotherapy of cancer, 11(Suppl 1), A24. https://doi.org/10.1136/jitc-2023-SITC2023.0022

Chicago Style (17th ed.) Citation

Willis, Elinor, Jillian Verrelle, Esha Banerjee, Charles-Antoine Assenmacher, James C. Tarrant, Nicolas Skuli, Moriah L. Jacobson, Zev Binder, and Enrico Radaelli. "22 Humanized NOG-EXL Mice Exhibit Improved Overall Survival and Less Severe Myeloid Cell Activation Relative to Humanized NSG-SGM3 Mice." Journal for Immunotherapy of Cancer 11, no. Suppl 1 (2023): A24. https://doi.org/10.1136/jitc-2023-SITC2023.0022.

MLA (9th ed.) Citation

Willis, Elinor, et al. "22 Humanized NOG-EXL Mice Exhibit Improved Overall Survival and Less Severe Myeloid Cell Activation Relative to Humanized NSG-SGM3 Mice." Journal for Immunotherapy of Cancer, vol. 11, no. Suppl 1, 2023, p. A24, https://doi.org/10.1136/jitc-2023-SITC2023.0022.